Guardant Health, Inc. (GH) Down 6.2% — Is This My Exit Signal?
Guardant Health, Inc. (GH) is giving back ground on Tuesday, last trading at $175.63 on the NASDAQ. That is an $11.59 decline from the prior close of $187.22. The pullback leaves the stock roughly 4.3% below its 52-week high of $183.51, set on September 17, 2026, and still about 188% above the 52-week low of $61.00. Few names in the space have traveled that far in a year, which puts a sharp single-session reversal like today's in context.
Volume stands at approximately 1.46 million shares with the session still underway, compared with a 90-day average of roughly 2.40 million. Turnover is tracking at about 61% of a typical full day.
Why Guardant Health, Inc. Price is Moving Lower
The most plausible explanation is profit-taking after a strong run, with a weak biotech tape adding to the pressure. GH gained 5.3% to $187.22 on October 5 after the COSMOS-MEL01 melanoma study was published in Cancer Research Communications. In 48 patients, Guardant Reveal detected 81% of distant recurrences with 100% post-treatment specificity. The blood test also flagged recurrence a median 70.5 days before clinical identification. Those are clean, positive results, and today's retreat looks like investors locking in gains on that news rather than any reassessment of the data. A same-day market report pointed to profit-taking after the recent run-up as the likely driver.
Sector conditions made it easier for sellers. The biotech ETF (XBI) fell 3.4% to $150.88, so part of GH's decline reflects broad weakness across biotech and diagnostics names. GH is down nearly twice as much as the index, though, which points to stock-specific selling on top of the sector drag. The broader Health Care group shows little of that strain. Boston Scientific Corporation (BSX) is up 0.01%, and Centene Corporation (CNC) is off a modest 0.72%. That gap suggests the pressure is concentrated in high-momentum biotech and diagnostics names rather than spread across the sector.
The fundamental backdrop entering this pullback is strong on growth but still costly to fund. Guardant's Q2 report on July 30 showed an adjusted loss of $0.42 per share, well ahead of the expected $0.76 loss. Revenue of $335.0 million beat the $314.23 million consensus and rose 44% from $232.1 million a year earlier. Management raised 2026 revenue guidance to $1.34 billion to $1.36 billion, up from $1.30 billion to $1.32 billion. It also widened expected free-cash-flow burn to $195 million to $205 million, from $185 million to $195 million. That trade-off, faster top-line growth bought with heavier spending, leaves a stock near its highs vulnerable to exactly this kind of profit-taking.
What is the Guardant Health, Inc. Rating - Should I Sell?
Weiss Ratings assigns GH a D- rating. The rating was upgraded on 8/15/2024. Current recommendation is Sell. The upgrade more than two years ago lifted the stock off the bottom of the scale, but a D- still signals a risk/reward profile that Weiss's framework does not support. The strength of the share price and the weakness of the underlying economics are pulling in opposite directions here.
The clearest positive is the Excellent rating on the Total Return Index. A climb from a 52-week low of $61.00 to a high of $183.51 has rewarded holders far more than most Health Care names, and even after today's decline the stock trades within a few percent of that peak. The Growth Index is rated Fair, which can look low for a company that posted 44.33% revenue growth. Revenue also rose 11.0% sequentially, from $301.67 million in the first quarter to $334.98 million in the second. That top-line expansion is real, but growth that keeps producing an EPS of -$3.50 and a forward P/E of -50.81 is not yet converting into earnings. That is why the rating stops at Fair.
Where the picture deteriorates is efficiency and risk. The Very Weak rating on the Efficiency Index reflects a -38.32% profit margin. For a test developer whose Guardant360 and Shield franchises already operate at commercial scale, that margin shows how far revenue still trails the cost of labs, sales and clinical evidence generation. The Fair rating on the Solvency Index fits the same story: the balance sheet is not under acute strain, but a free-cash-flow burn guided up to $195 million to $205 million keeps funding needs in view. The Weak Volatility Index shows up in today's trading. A 6.19% profit-taking drop immediately after a 5.3% gain, inside a 52-week range that spans $61.00 to $183.51, is the kind of swing that keeps this dimension from being rated higher.
Within the Health Care sector, Guardant trails Boston Scientific Corporation (BSX, D+), Medline Inc. (MDLN, D+) and Centene Corporation (CNC, D). None of those peers sits in Buy territory, which says something about caution across the group. Guardant still ranks below each of them, a reminder that its share-price momentum has run well ahead of its profitability.
About Guardant Health, Inc.
Guardant Health, Inc. (GH) is a precision oncology company in the Health Care sector. Incorporated in 2011 and headquartered in Palo Alto, California, the company provides blood and tissue tests and related data sets in the United States and internationally. Its flagship Guardant360 CDx is a liquid biopsy for tumor mutation profiling. The broader Guardant360 Liquid test measures more than 740 genes and supports all guideline-recommended biomarkers, while Guardant360 Tissue adds genomic, transcriptomic and epigenomic insight from tumor samples. Guardant Reveal uses circulating tumor DNA to detect cancer at the molecular level, the capability validated in the recent COSMOS-MEL01 melanoma study. The Shield blood test extends the portfolio into colorectal cancer screening for adults.
Beyond clinical testing, Guardant serves biopharmaceutical customers and researchers. GuardantINFINITY examines tumor molecular profiles and immune response to support therapy development. GuardantOMNI covers 500 genes, including those tied to homologous recombination repair deficiency and immuno-oncology biomarkers. GuardantINFORM pairs longitudinal tumor evolution data with clinical outcomes, and GuardantConnect is software that links tested patients carrying actionable alterations to relevant clinical studies. The company's Smart Platform delivers multiomic insights across genomic, epigenomic and RNA-based data, built to scale from research to the clinic.
Guardant also provides development services, including companion diagnostic development and regulatory approval, clinical study setup and monitoring, technology licensing, and kit fulfillment for Shield screening tests. It maintains a strategic oncology drug development collaboration with Nuvalent, Inc. Its competitive position rests on a broad menu that spans therapy selection, recurrence monitoring and screening, a growing body of clinical validation data, and established biopharma relationships. Together, those assets let Guardant follow patients across the cancer care continuum in a way narrower diagnostics competitors find difficult to match.
Investor Outlook
Guardant Health, Inc. (GH) carries a Weiss Rating of D- (Sell), and today's pullback is a reminder of how quickly a stock trading near its highs can reverse even on the back of positive clinical data. Investors should watch whether revenue continues tracking toward the raised $1.34 billion to $1.36 billion 2026 guidance. Equally important is whether free-cash-flow burn holds within the $195 million to $205 million range rather than expanding again. See full rankings of all D- rated Health Care stocks inside the Weiss Stock Screener.
--